HC Wainwright Has Negative Outlook of Savara FY2026 Earnings

Savara Inc (NASDAQ:SVRA) – HC Wainwright decreased their FY2026 EPS estimates for Savara in a report issued on Wednesday, May 28th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($0.45) for the year, down from their prior forecast of ($0.42). HC Wainwright has a “Neutral” rating and a $2.00 price objective on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Savara’s FY2027 earnings at ($0.31) EPS and FY2028 earnings at ($0.12) EPS.

Savara (NASDAQ:SVRA) last issued its earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, meeting analysts’ consensus estimates of ($0.12).

SVRA has been the subject of a number of other reports. Wells Fargo & Company lowered their price target on shares of Savara from $8.00 to $7.00 and set an “overweight” rating for the company in a report on Wednesday, May 28th. Evercore ISI lowered their price target on shares of Savara from $3.00 to $2.00 and set an “in-line” rating for the company in a report on Wednesday, May 28th. Finally, Guggenheim reaffirmed a “buy” rating and set a $8.00 price target (down from $9.00) on shares of Savara in a report on Wednesday, May 28th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $7.17.

Savara Price Performance

SVRA opened at $2.40 on Monday. The company has a fifty day simple moving average of $2.91 and a 200 day simple moving average of $2.94. The firm has a market cap of $414.81 million, a price-to-earnings ratio of -5.58 and a beta of 0.44. Savara has a twelve month low of $1.89 and a twelve month high of $5.11. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Cibc World Markets Corp acquired a new position in Savara during the 4th quarter worth $33,000. XTX Topco Ltd acquired a new position in Savara during the 4th quarter worth $34,000. Ameriprise Financial Inc. acquired a new position in Savara during the 4th quarter worth $37,000. KLP Kapitalforvaltning AS acquired a new position in Savara during the 4th quarter worth $41,000. Finally, Hsbc Holdings PLC acquired a new position in Savara during the 4th quarter worth $48,000. 87.93% of the stock is owned by institutional investors and hedge funds.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.